Research Library

A growing number of Brazilian companies are expanding internationally. These companies are part of the transformation reshaping the global investment environment. They have shifted their international strategy from being based exclusively on exports to becoming foreign investors in countries such as Peru, Chile, Colombia and Mexico.

Public finance fellow John Diamond analyzed the proposed Tax Reform Act of 2014 in testimony before the House Subcommittee on Select Revenue Measures on July 30, 2014.

The BRICS clearly want something tangible to demonstrate their global prominence and the power of non-Western values. Russell Green examines the critical issues that must be resolved before the BRICS bank can open its doors.

Neal Lane, senior fellow in science and technology policy, testified before the Senate Committee on Commerce, Science and Transportation on July 17, 2014. Lane is co-chair of the American Academy of Arts and Science's project on New Models for U.S. Science and Technology Policy, and his testimony addressed the project's objective of sustaining a long-term, nonpartisan, national focus on science and technology policy issues of vital importance to the country.

This issue brief examines the signals conveyed by Mexico's 2014 energy reforms, and analyzes the limitations in law, institutional design and policy that may delay, if not derail, the reforms' success.

This issue brief identifies the four main reforms that the new Prime Minister Narendra Modi’s government must undertake to revive the manufacturing industry in India.

By Steve Nolin

Following the legalization of retail marijuana sales in Colorado and Washington, and medical marijuana in…

Mexico's organized crime groups have expanded into areas that include the theft of crude oil, gas and gasoline. The impact of organized crime on the energy sector is a real threat to the intended effects of Mexico's energy reforms.

Cancer drug shortages are almost uniquely associated with generic drugs (small profit margins) and rarely with patented drugs (large profit margins). They are common in the U.S., but uncommon in Europe and elsewhere, where generic drug prices are on average higher than in the U.S. This suggests the main cause of drug shortages is economic.